Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Phosphodiesterase 3B (PDE3B) antagonizes the anti-angiogenic actions of PKA in human and murine endothelial cells.

MacKeil JL, Brzezinska P, Burke-Kleinman J, Theilmann AL, Nicol CJB, Ormiston ML, Maurice DH.

Cell Signal. 2019 Jun 5;62:109342. doi: 10.1016/j.cellsig.2019.06.007. [Epub ahead of print]

PMID:
31176020
2.

A PKA/cdc42 Signaling Axis Restricts Angiogenic Sprouting by Regulating Podosome Rosette Biogenesis and Matrix Remodeling.

MacKeil JL, Brzezinska P, Burke-Kleinman J, Craig AW, Nicol CJB, Maurice DH.

Sci Rep. 2019 Feb 20;9(1):2385. doi: 10.1038/s41598-018-37805-y.

3.

Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells.

Wilson LS, Guo M, Umana MB, Maurice DH.

Cell Signal. 2017 Aug;36:204-211. doi: 10.1016/j.cellsig.2017.04.019. Epub 2017 May 12.

PMID:
28506928
4.

Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients.

Selvam SN, Casey LJ, Bowman ML, Hawke LG, Longmore AJ, Mewburn J, Ormiston ML, Archer SL, Maurice DH, James P.

Blood Coagul Fibrinolysis. 2017 Oct;28(7):521-533. doi: 10.1097/MBC.0000000000000635.

5.

EPAC1 promotes adaptive responses in human arterial endothelial cells subjected to low levels of laminar fluid shear stress: Implications in flow-related endothelial dysfunction.

Rampersad SN, Freitag SI, Hubert F, Brzezinska P, Butler N, Umana MB, Wudwud AR, Maurice DH.

Cell Signal. 2016 Jun;28(6):606-19. doi: 10.1016/j.cellsig.2016.02.016. Epub 2016 Mar 14.

PMID:
26979996
6.

Leptin influences the excitability of area postrema neurons.

Smith PM, Brzezinska P, Hubert F, Mimee A, Maurice DH, Ferguson AV.

Am J Physiol Regul Integr Comp Physiol. 2016 Mar 1;310(5):R440-8. doi: 10.1152/ajpregu.00326.2015. Epub 2015 Dec 30.

7.

Adaptive phenotypic modulation of human arterial endothelial cells to fluid shear stress-encoded signals: modulation by phosphodiesterase 4D-VE-cadherin signalling.

Rampersad SN, Wudwud A, Hubert F, Maurice DH.

Cell Signal. 2016 Jul;28(7):741-8. doi: 10.1016/j.cellsig.2015.12.001. Epub 2015 Dec 4.

PMID:
26658094
8.

Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.

Giembycz MA, Maurice DH.

Curr Opin Pharmacol. 2014 Jun;16:89-107. doi: 10.1016/j.coph.2014.04.001. Epub 2014 May 6. Review.

PMID:
24810285
9.

Advances in targeting cyclic nucleotide phosphodiesterases.

Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC.

Nat Rev Drug Discov. 2014 Apr;13(4):290-314. doi: 10.1038/nrd4228. Review.

10.

Cyclic nucleotide phosphodiesterases (PDEs): coincidence detectors acting to spatially and temporally integrate cyclic nucleotide and non-cyclic nucleotide signals.

Maurice DH, Wilson LS, Rampersad SN, Hubert F, Truong T, Kaczmarek M, Brzezinska P, Freitag SI, Umana MB, Wudwud A.

Biochem Soc Trans. 2014 Apr;42(2):250-6. doi: 10.1042/BST20130268. Review.

PMID:
24646226
11.

PDE8A runs interference to limit PKA inhibition of Raf-1.

Maurice DH.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6248-9. doi: 10.1073/pnas.1303920110. Epub 2013 Apr 2. No abstract available.

12.

Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease.

Lee LC, Maurice DH, Baillie GS.

Future Med Chem. 2013 Mar;5(4):451-64. doi: 10.4155/fmc.12.216. Review.

13.

Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.

Hamilton TK, Hu N, Kolomitro K, Bell EN, Maurice DH, Graham CH, Siemens DR.

World J Urol. 2013 Apr;31(2):325-30. doi: 10.1007/s00345-012-0848-7. Epub 2012 Mar 2.

PMID:
22383129
14.

Subcellular signaling in the endothelium: cyclic nucleotides take their place.

Maurice DH.

Curr Opin Pharmacol. 2011 Dec;11(6):656-64. doi: 10.1016/j.coph.2011.10.009. Epub 2011 Oct 27. Review.

PMID:
22036169
15.

Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current.

Beca S, Helli PB, Simpson JA, Zhao D, Farman GP, Jones P, Tian X, Wilson LS, Ahmad F, Chen SRW, Movsesian MA, Manganiello V, Maurice DH, Conti M, Backx PH.

Circ Res. 2011 Oct 14;109(9):1024-1030. doi: 10.1161/CIRCRESAHA.111.250464. Epub 2011 Sep 8.

16.

A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells.

Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, Houslay MD, Maurice DH.

J Biol Chem. 2011 May 6;286(18):16285-96. doi: 10.1074/jbc.M110.217026. Epub 2011 Mar 10.

17.

Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability.

Rampersad SN, Ovens JD, Huston E, Umana MB, Wilson LS, Netherton SJ, Lynch MJ, Baillie GS, Houslay MD, Maurice DH.

J Biol Chem. 2010 Oct 29;285(44):33614-22. doi: 10.1074/jbc.M110.140004. Epub 2010 Aug 23.

18.

Distinct phosphodiesterase-4D variants integrate into protein kinase A-based signaling complexes in cardiac and vascular myocytes.

Raymond DR, Carter RL, Ward CA, Maurice DH.

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H263-71. doi: 10.1152/ajpheart.00425.2008. Epub 2008 Dec 5.

19.

Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions.

Wilson LS, Elbatarny HS, Crawley SW, Bennett BM, Maurice DH.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13650-5. doi: 10.1073/pnas.0804738105. Epub 2008 Aug 29.

20.

Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion.

Raymond DR, Wilson LS, Carter RL, Maurice DH.

Cell Signal. 2007 Dec;19(12):2507-18. Epub 2007 Aug 15.

PMID:
17884339
21.

Both protein kinase A and exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells.

Netherton SJ, Sutton JA, Wilson LS, Carter RL, Maurice DH.

Circ Res. 2007 Oct 12;101(8):768-76. Epub 2007 Aug 23.

PMID:
17717302
22.

PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.

Kerfant BG, Zhao D, Lorenzen-Schmidt I, Wilson LS, Cai S, Chen SR, Maurice DH, Backx PH.

Circ Res. 2007 Aug 17;101(4):400-8. Epub 2007 Jul 5.

PMID:
17615371
23.

Formation of extracellular matrix-digesting invadopodia by primary aortic smooth muscle cells.

Furmaniak-Kazmierczak E, Crawley SW, Carter RL, Maurice DH, Côté GP.

Circ Res. 2007 May 11;100(9):1328-36. Epub 2007 Apr 19.

PMID:
17446433
24.
25.

Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation.

Palmer D, Jimmo SL, Raymond DR, Wilson LS, Carter RL, Maurice DH.

J Biol Chem. 2007 Mar 30;282(13):9411-9. Epub 2007 Jan 25.

26.

Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases.

Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH.

Eur J Pharmacol. 2007 Mar 8;558(1-3):7-13. Epub 2006 Dec 1.

PMID:
17207790
27.

Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation.

MacPherson JD, Gillespie TD, Dunkerley HA, Maurice DH, Bennett BM.

J Pharmacol Exp Ther. 2006 Apr;317(1):188-95. Epub 2005 Dec 5.

PMID:
16330494
29.

Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex.

Elbatarny HS, Maurice DH.

Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E695-702. Epub 2005 May 10.

30.

Mechanism of tissue-selective drug action in the cardiovascular system.

Barrett TD, Triggle DJ, Walker MJ, Maurice DH.

Mol Interv. 2005 Apr;5(2):84-93. Review.

PMID:
15821157
31.
32.

Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.

Netherton SJ, Maurice DH.

Mol Pharmacol. 2005 Jan;67(1):263-72. Epub 2004 Oct 8.

PMID:
15475573
33.

Cardiovascular implications in the use of PDE5 inhibitor therapy.

Maurice DH.

Int J Impot Res. 2004 Jun;16 Suppl 1:S20-3. Review.

PMID:
15224131
34.
35.

Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system.

Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL.

Mol Pharmacol. 2003 Sep;64(3):533-46. Review.

PMID:
12920188
36.

Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis.

Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA.

J Biol Chem. 2003 Sep 26;278(39):37849-57. Epub 2003 Jul 16.

37.

Does sildenafil indirectly inhibit phosphodiesterase 3 in vascular smooth muscle?

Maurice DH.

Hypertension. 2003 Mar;41(3):e2. Epub 2003 Feb 10. No abstract available.

PMID:
12623968
38.
39.
40.

Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.

Netherton SJ, Jimmo SL, Palmer D, Tilley DG, Dunkerley HA, Raymond DR, Russell JC, Absher PM, Sage EH, Vernon RB, Maurice DH.

Diabetes. 2002 Apr;51(4):1194-200.

43.
44.

Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations.

Appleton SD, Chretien ML, McLaughlin BE, Vreman HJ, Stevenson DK, Brien JF, Nakatsu K, Maurice DH, Marks GS.

Drug Metab Dispos. 1999 Oct;27(10):1214-9.

PMID:
10497150
48.
49.

Collaborative and reciprocal effects of ciliary neurotrophic factor and nerve growth factor on the neuronal phenotype of human neuroblastoma cells.

Zinman LH, Lawrance G, Wang W, Verge VM, Dow KE, Maurice DH, Richardson PM, Riopelle RJ.

J Neurochem. 1998 Apr;70(4):1411-20.

50.

Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.

Rose RJ, Liu H, Palmer D, Maurice DH.

Br J Pharmacol. 1997 Sep;122(2):233-40.

Supplemental Content

Loading ...
Support Center